A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.
In order to select virus strains for the manufacture of Influenza Vaccine for 2004 Season, a meeting of the Australian Influenza Vaccine Committee on Influenza Vaccines was convened on 10 October 2002.
Having considered information on international surveillance by the World Health Organization (WHO), and up-to-date epidemiology and strain characterisation presented at the meeting, the Committee considered that the WHO recommendations on the composition of vaccines for 2004 Southern Hemisphere Season should be followed.
| A H1N1 strain: - | an A/New Caledonia/20/99(H1N1)-like strain A/New Caledonia/20/99 (IVR-116) is also recommended as a suitable vaccine strain. |
15 µg HA per dose. |
| A H3N2 strain: |
A/Fujian/411/2002(H3N2)-like strain |
15 µg HA per dose. |
| B Strain: | B/Hong Kong/330/2001-like strain B/Brisbane/32/2002 is also recommended as a suitable vaccine strain. |
15 µg HA per dose. |
Further details available on: www.tga.gov.au/docs/html/aivc2004.htm or
http://www.influenzacentre.org/
This article was published in Communicable Diseases Intelligence Volume 27 No 4, December 2003.
CDI Search
Communicable Diseases Intelligence subscriptions
Sign-up to email updates: Subscribe Now
Communicable Diseases Surveillance
This issue - Vol 27 No4, December 2003
Communicable Diseases Intelligence